NitiGoelMD
Rheumatology • Durham, NCAdjunct Assistant Professor in the Department of Medicine, Duke University School of Medicine and Co-founder, Caduceus Biomedical Consulting, LLC
Dr. Goel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
508 Fulton St
Durham, NC 27705Phone+1 828-257-2333
Education & Training
Duke University HospitalFellowship, Rheumatology, 1993 - 1995- Duke University HospitalResidency, Internal Medicine, 1990 - 1993
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1990
Certifications & Licensure
GA State Medical License 2008 - 2025
NC State Medical License 2016 - 2025
TX State Medical License 1996 - 2008- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Fellow American College of Rheumatology
Publications & Presentations
PubMed
- Hot Topics: Depression in Individuals With Psoriasis and Psoriatic Arthritis.Niti Goel, Elizabeth B Wallace, Christine Lindsay
The Journal of Rheumatology. 2024-10-01 - Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 Annual Meeting.Dafna D Gladman, Oliver FitzGerald, April W Armstrong, Niti Goel, Alice B Gottlieb
The Journal of Rheumatology. 2024-10-01 - 1 citationsEmbracing unity at OMERACT: Valuing equity, promoting diversity, fostering inclusivity.Lara J Maxwell, Grace C Wright, Grayson Schultz, Shawna Grosskleg, Jennifer L Barton
Seminars in Arthritis and Rheumatism. 2024-06-01
Press Mentions
Black, Hispanic Patients Underrepresented in PsA Clinical TrialsDecember 2nd, 2022- Abcuro to Present Late-Breaking Abstract at American College of Rheumatology Convergence 2021 of ABC008 Inclusion Body Myositis Phase 1 Data Demonstrating Proof of Mechanism for Selective Depletion of Highly Cytotoxic T CellsNovember 5th, 2021
Kezar Life Sciences Announces Promising Data from First in Patient Study of KZR-616 at EULAR 2019 Annual MeetingJune 13th, 2019- Join now to see all
Professional Memberships
- Member
Other Languages
- Hindi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
